share_log

bluebird bio | 8-K: Current report

bluebird bio | 8-K: Current report

bluebird bio | 8-K:重大事件
美股SEC公告 ·  2024/09/24 04:04

Moomoo AI 已提取核心訊息

On September 20, 2024, bluebird bio, Inc. entered into a Master Services Agreement with Henogen SRL, a subsidiary of Thermo Fisher Scientific, to manufacture lentiviral vector (LVV) used in bluebird bio's gene therapy product LYFGENIA. The agreement, effective as of September 15, 2024, supersedes the previous manufacturing contract with Henogen that expired on the same date. Henogen will be responsible for the production of LVV, including quality control, assurance, validation activities, stability testing, packaging, shipping, and other related services for both clinical and commercial use. The agreement allows for the creation of individual project agreements for specific products and requires bluebird bio to provide a 12-quarter rolling forecast for commercial LVV orders, with certain binding and semi-binding forecast periods. The contract is set to last until September 15, 2029, with automatic renewal for additional two-year terms unless terminated by either party due to material breach, bankruptcy proceedings, or force majeure events. It also includes standard provisions such as representations, warranties, limitations of liabilities, confidentiality, indemnity obligations, and other customary terms.
On September 20, 2024, bluebird bio, Inc. entered into a Master Services Agreement with Henogen SRL, a subsidiary of Thermo Fisher Scientific, to manufacture lentiviral vector (LVV) used in bluebird bio's gene therapy product LYFGENIA. The agreement, effective as of September 15, 2024, supersedes the previous manufacturing contract with Henogen that expired on the same date. Henogen will be responsible for the production of LVV, including quality control, assurance, validation activities, stability testing, packaging, shipping, and other related services for both clinical and commercial use. The agreement allows for the creation of individual project agreements for specific products and requires bluebird bio to provide a 12-quarter rolling forecast for commercial LVV orders, with certain binding and semi-binding forecast periods. The contract is set to last until September 15, 2029, with automatic renewal for additional two-year terms unless terminated by either party due to material breach, bankruptcy proceedings, or force majeure events. It also includes standard provisions such as representations, warranties, limitations of liabilities, confidentiality, indemnity obligations, and other customary terms.
2024年9月20日,bluebird bio與賽默飛世爾的子公司Henogen SRL簽署了一份主要服務協議,用於生產bluebird bio的基因治療產品LYFGENIA中使用的慢病毒載體(LVV)。該協議自2024年9月15日生效,取代了之前與Henogen簽署的於同一日期到期的製造合同。Henogen將負責生產LVV,包括質量控制、保證、驗證活動、穩定性測試、包裝、運輸以及其他臨床和商業用途相關服務。該協議允許爲特定產品創建個別項目協議,並要求bluebird bio提供爲商業LVV訂單提供爲期12個季度的滾動預測,具有某些具有約束力和半約束力的預測期。合同將持續至2029年9月15日,自動續約兩年,除非任何一方因重大違約、破產程序或不可抗力事件而終止。合同還包括諸如陳述、擔保、責任限制、保密性、補償義務和其他慣例條款等標準規定。
2024年9月20日,bluebird bio與賽默飛世爾的子公司Henogen SRL簽署了一份主要服務協議,用於生產bluebird bio的基因治療產品LYFGENIA中使用的慢病毒載體(LVV)。該協議自2024年9月15日生效,取代了之前與Henogen簽署的於同一日期到期的製造合同。Henogen將負責生產LVV,包括質量控制、保證、驗證活動、穩定性測試、包裝、運輸以及其他臨床和商業用途相關服務。該協議允許爲特定產品創建個別項目協議,並要求bluebird bio提供爲商業LVV訂單提供爲期12個季度的滾動預測,具有某些具有約束力和半約束力的預測期。合同將持續至2029年9月15日,自動續約兩年,除非任何一方因重大違約、破產程序或不可抗力事件而終止。合同還包括諸如陳述、擔保、責任限制、保密性、補償義務和其他慣例條款等標準規定。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息